A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
- Registration Number
- NCT05479058
- Lead Sponsor
- Galapagos NV
- Brief Summary
Participants who were in clinical remission on 200 milligram (mg) filgotinib once daily for at least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899, NCT02914535), were planned to be rolled over and randomized in this study. The primary objective of this study was to evaluate the efficacy of filgotinib in participants in stable clinical remission on 200 mg filgotinib once daily for whom the dose was decreased to 100 mg once daily compared to participants remaining on 200 mg once daily.
- Detailed Description
Participants were planned to receive the blinded treatment until primary analysis time point. After unblinding at the study primary analysis time point, participants would have received unblinded treatment. The clinical trial was originally designed with the primary endpoint to be assessed at Week 48. Due to early termination of the study, none of the participants completed 48 weeks of treatment. All participants participated in blinded treatment period only and the study was unblinded globally after study completion.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 22
-
Participants must have participated in the SELECTION-LTE study (GS-US-418-3899), who were on 200 mg filgotinib once daily and fulfilled the following conditions:
- partial Mayo Clinical Score remission over a period of at least 2 consecutive quarterly visits in the SELECTION-LTE study (GS-US-418-3899) prior to screening of the present study;
- free of corticosteroids for at least 12 weeks prior to and including baseline;
- fecal calprotectin (FCP) ≤250 microgram per gram (μg/g) at last observation within 6 months prior to screening or FCP ≤250 μg/g during the screening of the present study.
- sigmoidoscopy ES of 0 or 1 (local score) at screening.
-
Willing to refrain from live attenuated vaccines during the study and for 12 weeks after the last dose of filgotinib in the study.
-
Female participants of childbearing potential must have had a negative highly sensitive (serum beta human chorionic gonadotropin) pregnancy test during screening and must have agreed to continued monthly urine dipstick pregnancy testing during filgotinib treatment.
-
Female participants of childbearing potential must have agreed to use highly effective contraception measures as defined in the protocol.
Key
- Any chronic medical condition (including but not limited to, cardiac or pulmonary disease, alcohol, or drug abuse) that, in the opinion of the investigator or sponsor, would make the participant unsuitable for the study or would prevent compliance with the study protocol.
- Participant had a known hypersensitivity to filgotinib ingredients or history of a significant allergic reaction to filgotinib ingredients as determined by the investigator.
- Female participant who was pregnant or breastfeeding, or intended to become pregnant or breastfeed, and/or plans to undergo egg donation or egg harvesting for the purpose of current or future fertilization, during the study and until the end of the study.
- Participant was unable or unwilling to comply with restrictions regarding prior and concomitant medication as described in the protocol.
- Participant had a positive QuantiFERON® tuberculosis (TB) test at screening or had 2 indeterminate QuantiFERON® TB test results that required Investigational product (IP) treatment interruption, or participant had sign and symptoms of TB reactivation at screening.
- History of malignancy during or in the last 5 years prior to participation in the UC parent studies, except for participants who had been successfully treated for nonmelanoma skin cancer or cervical carcinoma in situ.
- Participant met discontinuation criteria of the SELECTION-LTE study (GS-US-418-3899).
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Filgotinib 200 mg Filgotinib Participants received filgotinib 200 mg and placebo to match filgotinib 100 mg once daily orally. Filgotinib 200 mg Placebo Participants received filgotinib 200 mg and placebo to match filgotinib 100 mg once daily orally. Filgotinib 100 mg Filgotinib Participants received filgotinib 100 mg and placebo to match filgotinib 200 mg once daily orally. Filgotinib 100 mg Placebo Participants received filgotinib 100 mg and placebo to match filgotinib 200 mg once daily orally.
- Primary Outcome Measures
Name Time Method Percentage of Participants in Corticosteroid-free Clinical Remission Based on Modified Mayo Clinical Score (mMCS) Week 48 The mMCS is a tool designed to measure disease activity for ulcerative colitis. The mMCS was calculated as the sum of the 3 subscores: stool frequency, rectal bleeding, and endoscopy. Each subscore was graded from 0 to 3 with higher scores indicating more severe disease activity. The total mMCS score ranged from 0 to 9 with higher scores indicating more severe disease activity.
The mMCS remission was defined as a total score of score ≤2, with endoscopic subscore of ≤1, stool frequency subscore of ≤1, and a rectal bleeding subscore of 0.
Corticosteroid-free mMCS remission was defined as being free of corticosteroids for at least 12 weeks.
- Secondary Outcome Measures
Name Time Method Time to Patient-Reported Outcome Based on 2 Items (PRO2) Flare Baseline up to Week 48 PRO2 flare was defined as a PRO2 score worsening of at least 2 points and an absolute PRO2 score of at least 3, with stool frequency subscore ≥2, and rectal bleeding subscore ≥1.
PRO2 included items of stool frequency and rectal bleeding. The range of each item score was 0 to 3 with higher scores indicating more severe disease.Time to ES-Confirmed UC Flare Baseline up to Week 48 An ES-confirmed UC flare was defined as an increase in rectal bleeding subscore by at least 1 point and an increase in stool frequency subscore by at least 2 points and an increase in endoscopic subscore by at least 1 point. Each subscore graded from 0 to 3 with higher scores indicating more severe disease.
Change From Baseline in C-Reactive Protein (CRP) Baseline, Week 4, Week 12, Week 24, Week 36, and Week 48 CRP is an acute-phase protein which provides an objective criterion of inflammatory activity.
Change From Baseline in Fecal Calprotectin (FCP) Baseline, Week 4, Week 12, Week 24, Week 36, and Week 48 Fecal calprotectin, a very stable biomarker, was a 36 kilodalton calcium and zinc binding protein of S-100 protein family which was neutrophil derived. It represents 60% of cytosolic proteins in neutrophils and was a measurement of neutrophil migration to the gastrointestinal tract.
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score Baseline, Week 48 The IBDQ is disease-specific questionnaire used for an assessment of Health Related Quality of Life (HRQoL) in participants with the Inflammatory Bowel Disease (IBD). It comprised of 32 questions divided into four health subscales: bowel symptoms (10 questions); systemic symptoms, including sleep disorders and fatigue (5 questions); emotional function such as depression, aggression, and irritation (12 questions); and social function, meaning the ability to participate in social activities and to work (5 questions). The IBDQ total score was calculated as the sum of the responses (each ranging from 1 \[severe problem\] to 7 \[normal health\]) to all 32 questions. Total IBDQ score ranged from 32 to 224 with a higher score indicating a better HRQoL.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and TEAEs Leading to Treatment Discontinuation Baseline up to Week 48 An adverse event (AE) was any untoward medical occurrence, new or worsening of any preexisting condition, in a clinical study participant administered a medicinal product and which did not necessarily had to have a causal relationship with this treatment.
A TEAE was defined as
* An AE which had a start date equal to or after the date of the first administration of study drug in this study and no later than 30 days after last administration of study drug.
* And was either a newly reported event, or a worsening of an existing event.
Serious TEAE was defined as a TEAE that
* Resulted in death and was life-threatening;
* Required in-patient hospitalization or prolongation of existing hospitalization;
* Resulted in persistent or significant disability/incapacity;
* Was a congenital anomaly / birth defect;
* Was medically significant.
Trial Locations
- Locations (50)
University of Miami
🇺🇸Miami, Florida, United States
Gastroenterology Group of Naples
🇺🇸Naples, Florida, United States
Gastro Center of Maryland - Columbia
🇺🇸Columbia, Maryland, United States
Rapid City Medical Center
🇺🇸Rapid City, South Dakota, United States
Gastroenterology Associates of Tidewater
🇺🇸Chesapeake, Virginia, United States
Universitair Ziekenhuis Leuven Campus Gasthuisberg
🇧🇪Leuven, Belgium
Hepato-Gastroenterology HK
🇨🇿Hradec Králové, Czechia
GEP Clinic
🇨🇿Praha, Czechia
CHU Amiens-Picardie
🇫🇷Amiens, France
Centre Hospitalier Universitaire Hôpital Nord Service D'Hépato-Gastro-Entérologie
🇫🇷Marseille, France
Scroll for more (40 remaining)University of Miami🇺🇸Miami, Florida, United States